Biotech Values

[DewDiligence]

SNY’s headline in this PR from ADA is misleading:

http://finance.yahoo.com/news/Sanofi-Announces-Positive-prnews-2993290208.html?x=0&.v=1

Sanofi Announces Positive Results from the "All to Target" Study Evaluating Two Lantus® and Apidra® Regimens Versus Premixed Regimen

In fact, this open-label study missed its main objective, which was to show that Lantus + Apidra was superior to Novolog 70/30. From the same PR:

The study results supported the non-inferiority of Lantus® plus up to 1 injection of Apidra® versus two–injections of premixed insulin, while in the Lantus® plus up to 3 injections of Apidra® arm, superiority versus premixed insulin was not shown.